ArticleProceedings of the National Academy of Sciences of the United States of America1994
Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 90 citations in OpenAlex.
- Fundamentals of Cancer Immunology and Their Application to Cancer Vaccines.Clinical and translational science · 2021Article
- NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.Gynecologic oncology · 2017Article
- Article
- Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody.International journal of nanomedicine · 2016Article
- Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin's lymphoma patients.Cancer immunology, immunotherapy : CII · 2012Article
- Article
- A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4⁺ and CD8⁺ T-cell as well as B-cell responses.Cancer immunology, immunotherapy : CII · 2011Article
- Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers.PloS one · 2011Article
- Selective cancer-germline gene expression in pediatric brain tumors.Journal of neuro-oncology · 2008Article
- Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.Proceedings of the National Academy of Sciences of the United States of America · 2005Article
- Biological functions of melanoma-associated antigens.World journal of gastroenterology · 2004Review
- CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells.Cancer research · 2002Article
- Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours.British journal of cancer · 2000Article
- NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens.British journal of cancer · 2000Article
- Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines.The Journal of experimental medicine · 2000Article
- Expression of MAGE-1 and -3 genes and gene products in human hepatocellular carcinoma.British journal of cancer · 1999Article
- Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes.The Journal of experimental medicine · 1999Article
- Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library.Proceedings of the National Academy of Sciences of the United States of America · 1998Article
- A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.The Journal of experimental medicine · 1998Article
- Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas.Proceedings of the National Academy of Sciences of the United States of America · 1996Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human MAGE-1 gene encodes a melanoma peptide antigen recognized by autologous cytotoxic T lymphocytes. To produce antibodies against the MAGE-1 gene product, several approaches were taken. Three oligopeptides were synthesized based on predicted MAGE-1 amino acid sequences and were used to generate rabbit anti-peptide anti-sera. In addition, a truncated MAGE-1 cDNA was cloned into an Escherichia coli expression vector, and recombinant protein was produced and purified. All three rabbit anti-peptide antisera showed reactivity against the immunizing peptide, and one reacted with the recombinant MAGE-1 protein by immunoblotting, but none reacted with cell lysates from MAGE-1 mRNA-positive cells. The recombinant MAGE-1 protein was then used for the generation of mouse monoclonal and rabbit polyclonal antibodies. One IgG1 monoclonal antibody, MA454, as well as rabbit polyclonal antisera recognized a 46-kDa protein in extracts of MAGE-1 mRNA-positive melanoma cell lines. The antibodies showed no apparent cross-reactivity with products of the closely related MAGE-2 and MAGE-3 genes. Serological typing of normal and tumor cell lysates was in full agreement with mRNA analysis, showing expression of MAGE-1 protein in MAGE-1 mRNA-positive testis and a subset of melanomas but not in MAGE-1 mRNA-negative normal or tumor tissues. Transfection of the MAGE-1 gene into a MAGE-1 mRNA-negative melanoma cell line resulted in the expression of the 46-kDa protein, confirming the identity of this protein as the MAGE-1 gene product.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.